---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-052542"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:54:31.314188+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026

## Summary
- API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
- All manufacturing payments completed; no additional cash outlays anticipated.
- Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
- Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.
- Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites.

## SEC filing metadata
- accession: 0001213900-26-052542
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/0001213900-26-052542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/ea0289243-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-052542
- JSON: https://secwatch.observer/filing/0001213900-26-052542.json
- Plain text: https://secwatch.observer/filing/0001213900-26-052542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.